OAC
OVID icon

OMERS Administration Corp’s Ovid Therapeutics OVID Stock Holding History

OMERS Administration Corp’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Sell
100,100
-25,200
-20% -$45.1K ﹤0.01% 894
2025
Q4 		$204K Buy
+125,300
New +$193K ﹤0.01% 912

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

OMERS Administration Corp's OVID Position: Q1 2026 in Review

OMERS Administration Corp reduced its Ovid Therapeutics (OVID) stake by 20% in Q1 2026, selling an estimated $45.1K and leaving 100,100 shares worth $222K. The position accounts for ﹤0.01% of the portfolio, ranked #894.

OMERS Administration Corp first reported a position in OVID in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • OMERS Administration Corp held 100,100 shares of Ovid Therapeutics worth $222K as of Q1 2026.
  • OMERS Administration Corp sold 25,200 Ovid Therapeutics shares in Q1 2026, an estimated $45.1K.
  • Ovid Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #894 holding.
  • OMERS Administration Corp first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.